Koedijk, Joost B. http://orcid.org/0000-0001-6463-3307
van der Werf, Inge
Penter, Livius http://orcid.org/0000-0002-9060-0207
Vermeulen, Marijn A.
Barneh, Farnaz
Perzolli, Alicia http://orcid.org/0000-0003-1302-0943
Meesters-Ensing, Joyce I. http://orcid.org/0000-0003-0780-9227
Metselaar, Dennis S.
Margaritis, Thanasis
Fiocco, Marta
de Groot-Kruseman, Hester A.
Moeniralam, Rubina
Bang Christensen, Kristina
Porter, Billie
Pfaff, Kathleen
Garcia, Jacqueline S. http://orcid.org/0000-0003-2118-6302
Rodig, Scott J.
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Hasle, Henrik http://orcid.org/0000-0003-3976-9231
Nierkens, Stefan
Belderbos, Mirjam E. http://orcid.org/0000-0002-6164-2918
Zwaan, C. Michel http://orcid.org/0000-0001-6892-8268
Heidenreich, Olaf http://orcid.org/0000-0001-5404-6483
Funding for this research was provided by:
Stichting Kinderen Kankervrij (329)
American Society of Hematology (scholarship)
Deutsche Forschungsgemeinschaft (BIH)
Deutsche Krebshilfe (Max Eder)
Conquer Cancer Foundation (CDA)
U.S. Department of Health & Human Services | NIH | Center for Scientific Review (P01CA229092)
Article History
Received: 28 February 2024
Revised: 2 August 2024
Accepted: 13 August 2024
First Online: 26 August 2024
Competing interests
: JSG reports serving on steering committee and receiving personal fees from AbbVie, Astellas Pharma, Genentech, and Servier and institutional research funds from AbbVie, Genentech, Pfizer, and AstraZeneca. SJR receives research support from Affimed, Merck, Bristol-Myers-Squibb, and is a member of the Scientific Advisory Board for Immunitas Therapeutics. CJW is an equity holder of BioNtech, Inc, receives research support from Pharmacyclics, and is a Scientific Advisory Board member of Repertoire, Aethon Therapeutics, and Adventris. CMZ receives institutional research support from Pfizer, Abbvie, Takeda, Jazz, Kura Oncology, Gilead, and Daiichi Sankyo, provides consultancy services for Kura Oncology, Bristol-Myers-Squibb, Novartis, Gilead, Incyte, Beigene, and Syndax, and serves on advisory committees for Novartis, Sanofi, and Incyte. O.H. receives institutional research support from Syndax and Roche. The remaining authors declare no competing financial interests.